Τίτλος:
Statins and myocardial infarction: Type, dose, and administration time: Does it matter?
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. © 2016 Elsevier Inc.
Συγγραφείς:
Papageorgiou, N.
Zacharia, E.
Briasoulis, A.
Androulakis, E.
Tousoulis, D.
Περιοδικό:
Trends in Cardiovascular Medicine
Εκδότης:
HANLEY & BELFUS-ELSEVIER INC
Λέξεις-κλειδιά:
atorvastatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; rosuvastatin; hydroxymethylglutaryl coenzyme A reductase inhibitor, blood clot lysis; cerebrovascular accident; contrast induced nephropathy; diabetes mellitus; dose response; drug efficacy; drug safety; drug tolerance; drug use; heart infarction; heart muscle revascularization; human; mortality; percutaneous coronary intervention; priority journal; Review; risk factor; ST segment elevation myocardial infarction; treatment duration; acute coronary syndrome; complication; coronary artery disease; dose calculation; drug administration; Dyslipidemias; primary prevention; procedures; risk assessment; secondary prevention; ST Elevation Myocardial Infarction; time factor; treatment outcome, Acute Coronary Syndrome; Coronary Artery Disease; Drug Administration Schedule; Drug Dosage Calculations; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Risk Assessment; Risk Factors; Secondary Prevention; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome
DOI:
10.1016/j.tcm.2016.01.001
